Christian U Blank

42PUBLICATIONS
249CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

|Oct 08, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Sabine E Breukers, Joleen J H Traets, Stan W van Dijk

|Oct 01, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

Judith M Versluis, Huma Shehwana, Robert Elens

|Sep 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Georgina V Long, Nitya Nair, Daniel Marbach

|Sep 22, 2025
Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape.

Francesca Fallarino, Christian U Blank

Pageof 7

Frequent Collaborators

11 joint publications

John B Haanen

11 joint publications

Georgina V Long

9 joint publications

Richard A Scolyer

9 joint publications

Ton N Schumacher